"aion" "loan"

Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) ("Beyond Medical" or the "Company") is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. ("Micron Technologies").

New Variant of COVID-19

In response to the discovery of a new COVID-19 variant the federal government of Canada is implementing a travel ban on several south African countries including South Africa, Mozambique, Namibia, Zimbabwe, Botswana, Lesotho and Eswatini. In addition to Canada, the European Union, Israel, Japan, India, and Great Britain have all imposed travel bans on numerous South African countries. The restrictions have been implemented following the discovery of a new variant of COVID-19 in South Africa. South Africa's Minister of Health, Joe Phaahla, stated, "Initially, it looked like some cluster outbreaks, but from yesterday, the indication came from our scientists from the Network of Genomic Surveillance that they were observing a new variant."

The World Health Organization (WHO) declared the new variant identified in South Africa, named "Omicron", as a "variant of concern". The WHO deems new variants to be either a "variant of interest" or a "variant of concern", the latter being the more serious of the two. Further, a statement issued by the WHO on Friday stated "this variant has a large number of mutations, some of which are concerning" and that evidence gathered thus far indicates that the variant carried a higher risk of reinfection than other variants.

Manufacturing Three-Ply Medical Grade Face Masks at Full Capacity

Micron Technologies has been manufacturing and selling three-ply medical grade Level 3 face masks in Delta, B.C. since August 2020. Micron Technologies is manufacturing three-ply medical grade face masks pursuant its Medical Device Establishment License issued by Health Canada. Micron Technologies is also registered with the U.S. Food and Drug Administration.

Micron Technologies is currently operating two shifts per day to manufacture three-ply medical grade face masks. The three-ply medical grade face masks, which feature an adjustable nose clip designed to protect both front-line workers and consumers, offer three layers of protection and conform to the American Society for Testing and Materials' F2100 Level 3 standards.

Products for Retail

As previously announced, Micron Technologies' medical grade face masks are available to purchase through Walmart, Amazon and Shopify. Micron Technologies' black medical grade three-ply masks have achieved the status of '#1 best seller' on Amazon.

Institutional customers and those who are interested in obtaining a quote for large size orders are encouraged to contact Milan@micronti.com or sales@micronti.com. Customers can also make orders directly at https://micronti.com.

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, B.C. The Company, through its subsidiary Micron Technologies, manufactures medical grade face masks. For further information contact:

Kal Malhi, CEO

The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.


This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.


The Conversation (0)

Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results

  • Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic 1 basis
  • Full-Year revenues of $8.76 billion, up 8% on a Reported basis and 7% on an Organic 1 basis
  • Full-Year revenue growth in Salix, International, Solta and Bausch + Lomb segments on both a Reported and Organic 1 basis
  • GAAP Net Loss Attributable to Bausch Health Companies Inc. of $39 million for the quarter and $592 million for the year
  • Adjusted EBITDA Attributable to Bausch Health Companies Inc. 1 of $869 million for the quarter, up 6%, and $3.0 billion for the year, in line with prior year

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" the "Company," "we" or "our") today announced its fourth-quarter and full-year 2023 financial results

"I am pleased that we delivered against the financial guidance we established at the beginning of 2023. During the year, we made meaningful progress in driving performance across each of our business segments, continued to focus on our balance sheet and liquidity, and made significant progress on our key R&D initiatives, all helping to position the Company for continued growth and performance. We are excited about the positive momentum in our business as we enter 2024 and will continue to prioritize advancing our pipeline, investing in initiatives to continue to drive growth, and positioning the Company for long-term success," said Thomas J. Appio, Chief Executive Officer, Bausch Health.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for fostamatinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Knight has previously submitted marketing authorization applications for fostamatinib in Colombia and Mexico.

"This submission of fostamatinib demonstrates Knight's continued execution of our strategy of leveraging our solid platform and expertise to bring innovative therapies for important unmet healthcare needs in Latin America," said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Upfront Tuition Coverage Is a Game-Changer for Medtronic Employees

MAPS program helped remove barriers to education; Candi Sneed becomes first link in a chain of future engineers

Candi Sneed had always been passionate about pursuing higher education and a career in engineering. However, the cost of tuition and the lack of flexibility in traditional academic programs have been a barrier for her. That was until she discovered the Medtronic Advancement Pathways and Skill-building (MAPS) program

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic reports third quarter fiscal 2024 financial results

Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S. business returns to growth; Raises full year guidance

Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Medical Technology Stocks to Keep On The Radar


The healthcare technology industry is one that offers investors a plethora of opportunities. With global healthcare spending soaring to approximately $8.3 trillion and nearly half of that amount allocated in the U.S. alone, the sector presents intriguing growth prospects. As the healthcare industry outpaces the overall global economy in growth, investors find themselves on the cusp of a promising market.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

Making Earlier Detection of Ovarian Cancer a Reality

Corporate Presentation February 2024

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer, using its novel patented CXCL10 biomarker.

Keep reading...Show less

Latest Press Releases

Related News